WAYNE, Pa.--(BUSINESS WIRE)--Embrella Cardiovascular™, Inc., the developer of a cerebral Embolic Protection Device, today announced the appointment of Jeffrey F. O’Donnell to the positions of Chairman and Chief Executive Officer. Mr. O’Donnell who recently served as President and CEO of PhotoMedex from 1999 to 2009, brings exceptional operational experience as well as extensive experience in the healthcare industry, merging a solid, traditional corporate background with emerging growth experience.
Mr. O’Donnell previously served as President and CEO from 1997 to 1999 for Radiance Medical Systems (originally Cardiovascular Dynamics). From 1994 to 1995, Mr. O’Donnell held the position of President and CEO of Kensey Nash Corporation. In 2005, Mr. O’Donnell was named LifeScience CEO of the year by the Eastern Technology Council. Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and Johnson & Johnson’s Orthopedic Division. Mr. O’Donnell is currently an outside Board Member of Endologix, Inc., Replication Medical, Inc., and is on the Medical Advisory Board of Safeguard Scientific. He is also a Venture Partner of BioStar Ventures.
“Jeff’s extensive background in cardiovascular medical devices will be a tremendous asset to Embrella,” said Dr. Louis A. Cannon, M.D., President of the Cardiac & Vascular Research Center of Northern Michigan and Founder and Senior Managing Director of BioStar Ventures. “Jeff’s leadership and expertise will pave the way for Embrella’s success.” BioStar Ventures was the lead investor in Embrella Cardiovascular’s Series B round.
“I am thrilled to be leading this company,” said Mr. O’Donnell. “Patients will clearly benefit from this new technology. We believe it will prove to decrease the neurological complications relative to high risk interventional cardiovascular procedures.”
Embrella Cardiovascular™, Inc. is now located on 880 E. Swedesford Road in Wayne, PA.
About Embrella Cardiovascular™, Inc.
Embrella Cardiovascular™, Inc. is dedicated to creating a new standard-of-care for cerebral embolic protection during cardiovascular procedures. Embrella Cardiovascular™, Inc. believes that this technology can be successfully utilized as a safe, efficient and cost effective method of preventing dangerous clot or debris from embolizing into the carotid arteries during cardiovascular procedures.
Contact:
Embrella Cardiovascular™, Inc. Priscilla Kulkarni, 610-783-1100 Business Administrator and Marketing Associate priscilla.kulkarni@embrella.net
